Article (Scientific journals)
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T.; Verhoef G.; Steel E. et al.
2019In Acta Haematologica, 142 (197-207)
Peer Reviewed verified by ORBi


Full Text
Publisher postprint (105.43 kB)

All documents in ORBi are protected by a user license.

Send to


Keywords :
Chronic myeloid leukaemia; Tyrosine kinase inhibitor; Treatment interruption/discontinuation; Molecular response; Imatinib; Nilotinib; Dasatinib; Ponatinib
Abstract :
[en] Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/ discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts.
Disciplines :
Author, co-author :
Devos T.
Verhoef G.
Steel E.
Mazure D.
Lewalle P.
Bron D.
Berneman Z.
Benghiat FS.
MIneur P.
Theunissen K.
Zachée P.
Doyen C.
Put N.
LEJEUNE, Marie ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Van Eygen K.
Havelange V.
Reusens M.
Pluymers W.
Peeters K.
More authors (9 more) Less
Language :
Title :
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Publication date :
Journal title :
Acta Haematologica
Publisher :
Karger, Basel, Switzerland
Volume :
Issue :
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 13 January 2021


Number of views
80 (8 by ULiège)
Number of downloads
169 (1 by ULiège)

Scopus citations®
Scopus citations®
without self-citations


Similar publications

Contact ORBi